Xencor (XNCR) Price & Analysis

Compare

356 Followers

XNCR Stock Chart & Stats

$12.03

-$0.21(-0.88%)

At close: Jan 08 4:00 PM EST

$12.03

-$0.21(-0.88%)

Day’s Range― - ―

52-Week Range$6.92 - $18.69

Previous CloseN/A

Volume126.93K

Average Volume (3M)680.15K

Market Cap

$882.26M

Enterprise Value$1.02B

Total Cash (Recent Filing)$547.73M

Total Debt (Recent Filing)$187.75M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

May 13, 2026

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding73,338,640

10 Day Avg. Volume916,787

30 Day Avg. Volume680,153

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)1.79

Price to Sales (P/S)9.05

P/FCF Ratio-8.22

Enterprise Value/Market Cap1.15

Enterprise Value/Revenue8.09

Enterprise Value/Gross Profit8.64

Enterprise Value/Ebitda-21.53

Forecast

1Y Price Target

$26.39

Price Target Upside119.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-2.84

Revenue Forecast (FY)$124.45M

Bulls Say, Bears Say

Bulls Say

Clinical Data Presentation And Enrollment MomentumClinical and preclinical data presentations for the TL1A programs at a major conference, together with continued enrollment in the Phase IIb study, could validate mechanisms and sustain program momentum toward later-stage decisions.

Dose Selection For Pivotal TrialsUpdated early clinical data for the lead T-cell engager programs are expected to determine recommended dosing for Phase 3 and enable initiation of pivotal studies, reducing dose uncertainty before definitive trials.

Platform Proof-of-conceptDemonstrated proof-of-concept across the Xtend and bispecific T-cell engager platforms supports broader pipeline value and increases the likelihood that multiple assets will advance successfully.

Bears Say

Patent Dispute Limiting RoyaltiesA patent disagreement that limits expected royalty income to ex-U.S. sales reduces anticipated cash inflows and could tighten the company's funding runway for pivotal studies.

Program Development ComplexityDevelopment planning for the CLDN6xCD3 program must account for multiple tumor types, adding clinical-path complexity and creating uncertainty around optimal indications and regulatory strategy.

Trial Safety And Dosing Preparation ErrorA dosing-preparation error that elevated early adverse effects and likely reduced efficacy increases the risk of negative trial readouts, protocol changes, and additional monitoring requirements.

Xencor News

Xencor reports receipt of notice of termination of license agreement from Roche

In a regulatory filing, Xencor (XNCR) disclosed that on March 4, the company received a notice of termination...

8d ago

CHRO

XNCR

Controversial Prasad leaving FDA, NYT reports

Dr. Vinay Prasad, who issued several controversial decisions, including having refused to accept Moderna’s (MRNA) application for a...

9d ago

AZN

BMY

Xencor expects cash to fund operations into mid-2028

Xenco announced that Alexion Pharmaceuticals informed Xencor (XNCR) that it has taken the position that the Licensee does...

13d ago

XNCR

3 Best Stocks to Buy Today, 2/26/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

18d ago

ADTN

LIFE

Xencor price target raised to $27 from $26 at Barclays

Barclays raised the firm’s price target on Xencor (XNCR) to $27 from $26 and keeps an Overweight rating...

19d ago

XNCR

Xencor files automatic mixed securities shelf

16:31 EST Xencor (XNCR) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

20d ago

XNCR

Xencor reports Q4 EPS (9c), consensus (58c)

Reports Q4 revenue $28.2M, consensus $30M. “Xencor’s (XNCR) lead oncology drug candidate is XmAb819, a novel first-in-class T-cell...

20d ago

XNCR

Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors

Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. This Xencor, Inc. study tests first-line treatment...

4d ago

XNCR

Xencor, Genentech to End Protein Therapeutics Collaboration

Xencor ( ($XNCR) ) just unveiled an update. Xencor, Inc., a biopharmaceutical developer of engineered protein therapeutics, has...

8d ago

XNCR

Xencor: Buy Rating Reaffirmed on Pipeline Momentum Despite Ultomiris Royalty Headwind

William Blair analyst Matt Phipps has reiterated their bullish stance on XNCR stock, giving a Buy rating on...

13d ago

XNCR

Xencor Updates Outlook Amid Ultomiris Royalty Dispute

The latest update is out from Xencor ( ($XNCR) ). On March 2, 2026, Alexion Pharmaceuticals, Inc., licensee...

13d ago

XNCR

Buy Rating on Xencor: Advancing T-Cell Engagers and Diversified Pipeline Support Favorable Risk‑Reward

William Blair analyst Matt Phipps has maintained their bullish stance on XNCR stock, giving a Buy rating today....

19d ago

XNCR

Xencor price target raised to $20 from $17 at BofA

BofA raised the firm’s price target on Xencor (XNCR) to $20 from $17 and keeps a Neutral rating...

2M ago

XNCR

Xencor price target raised to $26 from $23 at Barclays

Barclays raised the firm’s price target on Xencor (XNCR) to $26 from $23 and keeps an Overweight rating...

3M ago

XNCR

XNCR FAQ

What was Xencor Inc’s price range in the past 12 months?

Xencor Inc lowest stock price was $6.92 and its highest was $18.69 in the past 12 months.

What is Xencor Inc’s market cap?

Xencor Inc’s market cap is $882.26M.

When is Xencor Inc’s upcoming earnings report date?

Xencor Inc’s upcoming earnings report date is May 13, 2026 which is in 57 days.

How were Xencor Inc’s earnings last quarter?

Xencor Inc released its earnings results on Feb 25, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.601 by $0.511.

Is Xencor Inc overvalued?

According to Wall Street analysts Xencor Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xencor Inc pay dividends?

Xencor Inc does not currently pay dividends.

What is Xencor Inc’s EPS estimate?

Xencor Inc’s EPS estimate is -0.67.

How many shares outstanding does Xencor Inc have?

Xencor Inc has 73,338,640 shares outstanding.

What happened to Xencor Inc’s price movement after its last earnings report?

Xencor Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.601. Following the earnings report the stock price went up 13.105%.

Which hedge fund is a major shareholder of Xencor Inc?

Currently, no hedge funds are holding shares in XNCR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Xencor Stock Smart Score

Underperform

Fundamentals

Return on Equity

-14.58%

Trailing 12-Months

Asset Growth

-8.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Xencor (XNCR) Earnings & Revenues

Historic Earnings Reports

XNCR Stock 12 Month Forecast

Average Price Target

$26.39

▲(119.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","25":"$25","44":"$44","15.5":"$15.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$43.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.5,25,34.5,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,14.661538461538463,17.023076923076925,19.384615384615387,21.746153846153845,24.10769230769231,26.46923076923077,28.83076923076923,31.192307692307693,33.55384615384615,35.91538461538462,38.27692307692308,40.63846153846154,{"y":43,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,13.383846153846154,14.467692307692309,15.551538461538463,16.635384615384616,17.71923076923077,18.803076923076922,19.88692307692308,20.970769230769232,22.054615384615385,23.13846153846154,24.222307692307695,25.306153846153848,{"y":26.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,12.333846153846155,12.367692307692309,12.401538461538463,12.435384615384615,12.46923076923077,12.503076923076923,12.536923076923078,12.570769230769232,12.604615384615386,12.638461538461538,12.672307692307692,12.706153846153846,{"y":12.74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >